Figure 8.
Role of AT1 receptor and glycolysis in glucose consumption in AFs with AngII stimulation. Conditioned media glucose concentrations were monitored at 48-h time points with AngII (AII) or vehicle (veh: 0.1% H2O final) treatment in purchased AFs pretreated with vehicle (veh: 0.1% DMSO final), 1 mM 2DG, or 10 μM Olmesartan (ARB) in MG-DMEM (A). Upon 48-h incubation, glucose consumption rates were determined (B). ECARs were determined with 100 nM AngII (AII) or vehicle (veh: H2O) treatment with a glycolysis stress test kit (C). One-way ANOVA with post hoc Tukey’s test showed *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. Data represent means ± SE from independent experiments (n = 5, A and B) and 5 replicates (C) as indicated. AF, adventitial fibroblast; ARB, AngII receptor blocker; AT1, receptor angiotensin II type-1 receptor; ECAR, extracellular acidification rate; G, glycolysis; GC, glycolytic capacity; GR, glycolytic reserve; NGA, nonglycolytic acidification.